출혈성 질환 치료 시장 - 세계 산업 규모, 점유율, 동향, 기회, 예측 : 약물 유형별, 질환 유형별, 유통 채널별, 최종사용자별, 지역별 및 경쟁 상황(2021-2031년)
Bleeding Disorders Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Drug Type, By Disease Type, By Distribution Channel, By End User, By Region & Competition, 2021-2031F
상품코드:1914674
리서치사:TechSci Research
발행일:2026년 01월
페이지 정보:영문 185 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
한글목차
세계의 출혈성 질환 치료 시장은 견조한 성장할 것으로 예상되며, 2025년 178억 1,000만 달러에서 2031년까지 298억 2,000만 달러로 확대되고, CAGR은 8.97%로 예측됩니다.
이 분야는 혈우병 A, 혈우병 B, 폰 빌레브란트병과 같은 선천성 질환의 관리에 필수적인 응고인자 대체요법 및 비인자제제를 포함한 다양한 약리학적 중재를 포괄하고 있습니다. 시장 확대는 주로 유전성 응고장애 진단율의 증가와 환자가 중요한 치료를 받을 수 있는 기회를 확대하기 위한 정부 주도의 조치에 의해 주도되고 있습니다. 또한, 반감기 연장 제품의 도입이 큰 원동력이 되고 있습니다. 이러한 치료법은 잦은 투약의 부담을 줄이고 예방적 치료 계획의 장기적인 순응도를 높일 수 있기 때문입니다.
시장 개요
예측 기간
2027-2031년
시장 규모 : 2025년
178억 1,000만 달러
시장 규모 : 2031년
298억 2,000만 달러
CAGR : 2026-2031년
8.97%
가장 빠르게 성장하는 부문
혈장 유래 응고인자 농축제제
최대 시장
아시아태평양
이러한 긍정적인 진전에도 불구하고, 평생에 걸친 치료의 막대한 비용이 큰 장벽으로 작용하고 있으며, 의료 예산이 제한적이고 상환 시스템이 불충분한 개발도상국에서는 접근성을 제한하고 있습니다. 이러한 재정적 장벽은 전 세계적으로 환자 발견과 질병 관리의 일관성 모두에 영향을 미치고 있습니다. 2024년 발표된 세계혈우연맹의 '2023년 세계 혈우병 실태조사 보고서'에 따르면, 전 세계적으로 출혈성 질환으로 진단받은 환자 수가 누적 46만 5,327명에 달해 지속적인 치료가 필요한 환자들이 많다는 사실이 밝혀져 지속적인 치료가 필요한 환자들이 많다는 것을 알 수 있습니다. 환자들의 존재를 부각시켰습니다.
시장 촉진요인
유전자 치료와 새로운 생물학적 제제의 상용화가 가속화되면서 시장은 변혁의 길로 접어들고 있습니다. 이는 만성 관리에서 잠재적인 근본 치료로 초점을 옮기고 있습니다. 이러한 발전에는 근본적인 유전적 요인을 교정하는 일회성 치료의 승인, 잦은 주입이 필요 없는 장기적인 보호가 포함됩니다. 이러한 첨단 치료법은 고가의 가격 책정을 수반하며 희귀질환 치료제에 대한 새로운 상환 기준을 확립하고 있습니다. 예를 들어, 화이자는 2024년 4월 '미국 FDA, 화이자의 BEQVEZ(TM) 승인'이라는 보도자료를 통해 중등도에서 중증의 성인 혈우병 B형 혈우병 환자를 위한 유전자 치료제의 승인을 발표했으며, 350만 달러의 정가를 책정했습니다. 이는 희귀 출혈성 질환 관리에 있어 임상적, 경제적으로 큰 전환점이 될 것입니다.
동시에 피하투여와 반감기 연장형 치료제의 등장으로 필요시 치료에서 예방적 치료로의 전환이 빠르게 진행되고 있습니다. 환자들은 기존 치료에 따른 물류 문제를 줄이면서 높은 응고 수준을 유지하고 관절 건강을 보호할 수 있는 새로운 약물을 점점 더 많이 채택하고 있습니다. 이러한 대안의 상업적 영향은 급속한 보급을 통해 알 수 있습니다. 사노피가 2024년 10월 발표한 '2024년 3분기 실적'에 따르면, ALTUVIIIO의 매출은 3분기에만 1억 7,200만 유로에 달했습니다. 마찬가지로, 2024년 2월 로슈가 발표한 '2023년 연례 보고서'에 따르면, 항체 치료제 헴리브라의 연간 매출액이 41억 스위스 프랑에 달해 예방 관리에서 비인자 요법의 우위를 확인했습니다.
시장의 과제
평생 치료에 따른 고비용은 전 세계 출혈성 질환 치료제 시장의 발전에 큰 장벽으로 작용하고 있습니다. 응고인자 제제 및 첨단 비응고인자 대체요법의 높은 비용으로 인해 제한된 예산으로 운영되는 의료 시스템에서 이러한 중요한 약물을 구하기 어려운 실정입니다. 공적 상환 시스템이 잘 갖추어지지 않은 지역에서는 이러한 재정적 압박이 표준 예방적 치료의 보급을 방해하고 있습니다. 그 결과, 시장은 진단을 받은 환자군의 상당 부분을 치료제의 적극적인 사용자로 전환하는 데 어려움을 겪고 있으며, 이는 신흥국 시장에서의 수익 기회를 제한하고 있습니다.
이러한 경제적 제약으로 인해 전 세계 시장 침투율과 제품 사용률에 큰 격차가 발생하고 있습니다. 세계혈우연맹의 데이터, 특히 2024년에 발표된 '2023년 세계 조사 보고서'에 따르면, 고소득 국가의 1인당 평균 응고인자 8인자 소비량은 6.64 국제단위인 반면, 저소득 국가에서는 0.00 국제단위에 불과합니다. 이러한 현저한 격차는 치료비 상승이 개발도상국의 시장 규모와 상업적 확장을 직접적으로 저해하고 경제적 가치의 대부분을 선진국에 집중시키고 있는 현실을 보여줍니다.
시장 동향
억제인자 관리를 위한 신규 리밸런싱 제제의 개발은 단순히 부족한 응고인자를 보충하는 것이 아니라 항응고 경로에 초점을 맞춰 새로운 치료 패러다임을 창출하고 있습니다. 기존의 응고인자 보충요법이나 이중특이성항체와는 달리 항조직인자 경로 억제제(anti-TFPI)나 소간섭 RNA(siRNA) 요법 등의 약제는 천연 항응고 물질을 억제하여 지혈 기능을 재확립합니다. 이 기전은 표준치료에 대한 억제인자를 가진 환자들에게 특히 중요하며, 예방을 위한 간편한 우회요법을 제공합니다. 노보노디스크가 지난 7월 'FDA, 알헤모 승인' 보도자료를 통해 밝힌 바와 같이, 항TFPI 요법이 Explorer8 임상 3상 시험에서 억제인자가 없는 B형 혈우병 환자의 연간 출혈률을 통계적으로 유의미하게 79% 감소시킨 것으로 나타났습니다. 감소시킨 것으로 입증되었습니다.
이와 함께 CRISPR-Cas9 유전자 편집 기술의 응용은 1세대 바이러스 벡터 유전자 치료의 한계를 뛰어넘고 있습니다. 현재의 접근법은 주로 아데노 부속 바이러스(AAV) 벡터에 의존하여 유전자를 도입하는 반면, CRISPR 기술은 환자의 유전체를 체외 또는 체내에서 정밀하게 편집할 수 있어 면역원성 위험이 낮고 보다 지속적이고 영구적인 기능적 치료의 가능성을 제공합니다. 이러한 추세는 응고장애를 유발하는 특정 유전자 변이를 타겟으로 전임상 연구에서 인체 임상시험으로 빠르게 전환되고 있습니다. 예를 들어, 비바이오파마는 2025년 7월 보도자료 '비바이오, 첫 피험자 투여 발표'를 통해 자체 개발한 CRISPR-Cas9 기술을 이용한 B세포 치료제 BE-101을 임상 평가 단계로 전환하고, I/II상 시험으로 혈우병 B형 성인 환자 24명 등록을 목표로 한다고 발표했습니다. 을 발표하였습니다.
The Global Bleeding Disorders Treatment Market is projected to experience robust growth, increasing from a valuation of USD 17.81 Billion in 2025 to USD 29.82 Billion by 2031, reflecting a compound annual growth rate of 8.97%. This sector encompasses a range of pharmacological interventions, including clotting factor replacement therapies and non-factor agents, which are essential for managing congenital conditions such as hemophilia A, hemophilia B, and von Willebrand disease. The market's expansion is primarily fueled by rising diagnosis rates for genetic coagulation defects and government initiatives designed to enhance patient access to critical care. Furthermore, the introduction of extended-half-life products acts as a major catalyst, as these therapies alleviate the burden of frequent administration and promote long-term adherence to prophylactic treatment plans.
Market Overview
Forecast Period
2027-2031
Market Size 2025
USD 17.81 Billion
Market Size 2031
USD 29.82 Billion
CAGR 2026-2031
8.97%
Fastest Growing Segment
Plasma-Derived Coagulation Factor Concentrates
Largest Market
Asia Pacific
Despite these positive developments, the exorbitant cost of lifelong therapy presents a significant obstacle, restricting access in developing nations where healthcare budgets are limited and reimbursement structures are inadequate. This financial barrier impacts both the identification of patients and the consistency of disease management on a global scale. Highlighting the magnitude of the need for sustained therapeutic support, the World Federation of Hemophilia's Report on the Annual Global Survey 2023, published in 2024, recorded a cumulative total of 465,327 individuals diagnosed with bleeding disorders worldwide, underscoring the vast population requiring ongoing care.
Market Driver
The market is being transformed by the accelerated commercialization of gene therapies and novel biologics, which are shifting the focus from chronic management to potential cures. This evolution involves the approval of one-time treatments that correct underlying genetic causes, providing long-term protection without the need for frequent infusions. These advanced therapies command premium prices, establishing new reimbursement benchmarks for orphan drugs. For example, Pfizer Inc. announced in an April 2024 press release titled "U.S. FDA Approves Pfizer's BEQVEZ(TM)" that regulators had approved their gene therapy for adults with moderate to severe hemophilia B, assigning it a list price of $3.5 million, marking a significant clinical and economic shift in managing rare bleeding disorders.
Simultaneously, there is a strong movement from on-demand care to prophylactic regimens, driven by the availability of subcutaneous and extended-half-life therapies. Patients are increasingly adopting these novel agents because they maintain higher coagulation levels and protect joint health while reducing the logistical challenges associated with traditional treatments. The commercial impact of these options is demonstrated by their rapid adoption; according to Sanofi's "Q3 2024 Earnings" presentation in October 2024, sales of ALTUVIIIO reached €172 million in just the third quarter. Similarly, Roche reported in their "Annual Report 2023" from February 2024 that the antibody Hemlibra achieved full-year sales of CHF 4.1 billion, confirming the dominance of non-factor therapies in prophylactic management.
Market Challenge
The prohibitive expense associated with lifelong treatment acts as a substantial hurdle to the growth of the Global Bleeding Disorders Treatment Market. The high costs of clotting factors and advanced non-factor replacement therapies make these vital medications unaffordable for healthcare systems operating with restricted budgets. In areas lacking robust public reimbursement schemes, this financial pressure hinders the widespread implementation of standard prophylactic care. As a result, the market struggles to convert a significant proportion of the diagnosed patient population into active users of therapeutic products, thereby constraining revenue opportunities in emerging economies.
This economic limitation fosters a sharp divide in global market penetration and product usage. Data from the World Federation of Hemophilia, specifically the Report on the Annual Global Survey 2023 published in 2024, indicated that while the median per capita consumption of Factor VIII was 6.64 International Units in high-income nations, it remained at 0.00 International Units in low-income countries. This stark disparity underscores how elevated treatment costs directly obstruct market volume and commercial expansion in developing regions, effectively concentrating the majority of economic value within developed nations.
Market Trends
The development of novel rebalancing agents for inhibitor management is creating a new therapeutic paradigm by focusing on anticoagulation pathways instead of merely replacing missing clotting factors. Distinct from traditional factor replacements or bispecific antibodies, agents such as anti-tissue factor pathway inhibitors (anti-TFPI) and small interfering RNA (siRNA) therapies work by suppressing natural anticoagulants to re-establish hemostasis. This mechanism is especially crucial for patients with inhibitors to standard treatments, offering a simplified bypass solution for prophylaxis. The clinical value of this approach was evidenced when Novo Nordisk announced in a July 2025 press release titled "FDA approves Alhemo" that their anti-TFPI therapy achieved a statistically significant 79% reduction in the annualized bleeding rate for Hemophilia B patients without inhibitors during the explorer8 Phase 3 trial.
In parallel, advancements in CRISPR-Cas9 gene editing applications are evolving beyond the limitations of first-generation viral vector gene therapies. While current approaches largely depend on adeno-associated virus (AAV) vectors for gene addition, CRISPR technology facilitates precise ex vivo or in vivo editing of the patient's genome, offering the potential for a more durable, permanent functional cure with lower immunogenicity risks. This trend is rapidly transitioning from preclinical studies to human trials, targeting the specific genetic mutations causing coagulation deficits. For instance, Be Biopharma announced in a July 2025 press release titled "Be Bio Announces First Participant Dosed" that it had moved its proprietary CRISPR-Cas9 engineered B cell medicine, BE-101, into clinical evaluation with a Phase 1/2 study aiming to enroll 24 adults with Hemophilia B.
Key Market Players
Takeda Pharmaceutical Company Limited
Roche Holding AG
Novo Nordisk A/S
Pfizer Inc.
Bayer AG
Sanofi S.A.
Baxter International Inc.
Grifols, S.A.
Swedish Orphan Biovitrum AB
Octapharma AG
Report Scope
In this report, the Global Bleeding Disorders Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Bleeding Disorders Treatment Market, By Drug Type
Plasma-derived Coagulation Factor Concentrates
Recombinant Coagulation Factor Concentrates
Desmopressin
Antifibrinolytics
Fibrin Sealants
Others
Bleeding Disorders Treatment Market, By Disease Type
Hemophilia A
Hemophilia B
Von Willebrand Disease
Others
Bleeding Disorders Treatment Market, By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online
Bleeding Disorders Treatment Market, By End User
Clinics
Hospitals
Research Institutes
Others
Bleeding Disorders Treatment Market, By Region
North America
United States
Canada
Mexico
Europe
France
United Kingdom
Italy
Germany
Spain
Asia Pacific
China
India
Japan
Australia
South Korea
South America
Brazil
Argentina
Colombia
Middle East & Africa
South Africa
Saudi Arabia
UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Bleeding Disorders Treatment Market.
Available Customizations:
Global Bleeding Disorders Treatment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
Detailed analysis and profiling of additional market players (up to five).
Table of Contents
1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Global Bleeding Disorders Treatment Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Drug Type (Plasma-derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Desmopressin, Antifibrinolytics, Fibrin Sealants, Others)
5.2.2. By Disease Type (Hemophilia A, Hemophilia B, Von Willebrand Disease, Others)
5.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online)
5.2.4. By End User (Clinics, Hospitals, Research Institutes, Others)
5.2.5. By Region
5.2.6. By Company (2025)
5.3. Market Map
6. North America Bleeding Disorders Treatment Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Drug Type
6.2.2. By Disease Type
6.2.3. By Distribution Channel
6.2.4. By End User
6.2.5. By Country
6.3. North America: Country Analysis
6.3.1. United States Bleeding Disorders Treatment Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Drug Type
6.3.1.2.2. By Disease Type
6.3.1.2.3. By Distribution Channel
6.3.1.2.4. By End User
6.3.2. Canada Bleeding Disorders Treatment Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Drug Type
6.3.2.2.2. By Disease Type
6.3.2.2.3. By Distribution Channel
6.3.2.2.4. By End User
6.3.3. Mexico Bleeding Disorders Treatment Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Drug Type
6.3.3.2.2. By Disease Type
6.3.3.2.3. By Distribution Channel
6.3.3.2.4. By End User
7. Europe Bleeding Disorders Treatment Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Drug Type
7.2.2. By Disease Type
7.2.3. By Distribution Channel
7.2.4. By End User
7.2.5. By Country
7.3. Europe: Country Analysis
7.3.1. Germany Bleeding Disorders Treatment Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Drug Type
7.3.1.2.2. By Disease Type
7.3.1.2.3. By Distribution Channel
7.3.1.2.4. By End User
7.3.2. France Bleeding Disorders Treatment Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Drug Type
7.3.2.2.2. By Disease Type
7.3.2.2.3. By Distribution Channel
7.3.2.2.4. By End User
7.3.3. United Kingdom Bleeding Disorders Treatment Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Drug Type
7.3.3.2.2. By Disease Type
7.3.3.2.3. By Distribution Channel
7.3.3.2.4. By End User
7.3.4. Italy Bleeding Disorders Treatment Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Drug Type
7.3.4.2.2. By Disease Type
7.3.4.2.3. By Distribution Channel
7.3.4.2.4. By End User
7.3.5. Spain Bleeding Disorders Treatment Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Drug Type
7.3.5.2.2. By Disease Type
7.3.5.2.3. By Distribution Channel
7.3.5.2.4. By End User
8. Asia Pacific Bleeding Disorders Treatment Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Drug Type
8.2.2. By Disease Type
8.2.3. By Distribution Channel
8.2.4. By End User
8.2.5. By Country
8.3. Asia Pacific: Country Analysis
8.3.1. China Bleeding Disorders Treatment Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Drug Type
8.3.1.2.2. By Disease Type
8.3.1.2.3. By Distribution Channel
8.3.1.2.4. By End User
8.3.2. India Bleeding Disorders Treatment Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Drug Type
8.3.2.2.2. By Disease Type
8.3.2.2.3. By Distribution Channel
8.3.2.2.4. By End User
8.3.3. Japan Bleeding Disorders Treatment Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Drug Type
8.3.3.2.2. By Disease Type
8.3.3.2.3. By Distribution Channel
8.3.3.2.4. By End User
8.3.4. South Korea Bleeding Disorders Treatment Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Drug Type
8.3.4.2.2. By Disease Type
8.3.4.2.3. By Distribution Channel
8.3.4.2.4. By End User
8.3.5. Australia Bleeding Disorders Treatment Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Drug Type
8.3.5.2.2. By Disease Type
8.3.5.2.3. By Distribution Channel
8.3.5.2.4. By End User
9. Middle East & Africa Bleeding Disorders Treatment Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Drug Type
9.2.2. By Disease Type
9.2.3. By Distribution Channel
9.2.4. By End User
9.2.5. By Country
9.3. Middle East & Africa: Country Analysis
9.3.1. Saudi Arabia Bleeding Disorders Treatment Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Drug Type
9.3.1.2.2. By Disease Type
9.3.1.2.3. By Distribution Channel
9.3.1.2.4. By End User
9.3.2. UAE Bleeding Disorders Treatment Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Drug Type
9.3.2.2.2. By Disease Type
9.3.2.2.3. By Distribution Channel
9.3.2.2.4. By End User
9.3.3. South Africa Bleeding Disorders Treatment Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Drug Type
9.3.3.2.2. By Disease Type
9.3.3.2.3. By Distribution Channel
9.3.3.2.4. By End User
10. South America Bleeding Disorders Treatment Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Drug Type
10.2.2. By Disease Type
10.2.3. By Distribution Channel
10.2.4. By End User
10.2.5. By Country
10.3. South America: Country Analysis
10.3.1. Brazil Bleeding Disorders Treatment Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Drug Type
10.3.1.2.2. By Disease Type
10.3.1.2.3. By Distribution Channel
10.3.1.2.4. By End User
10.3.2. Colombia Bleeding Disorders Treatment Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Drug Type
10.3.2.2.2. By Disease Type
10.3.2.2.3. By Distribution Channel
10.3.2.2.4. By End User
10.3.3. Argentina Bleeding Disorders Treatment Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Drug Type
10.3.3.2.2. By Disease Type
10.3.3.2.3. By Distribution Channel
10.3.3.2.4. By End User
11. Market Dynamics
11.1. Drivers
11.2. Challenges
12. Market Trends & Developments
12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments
13. Global Bleeding Disorders Treatment Market: SWOT Analysis
